Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07455617) titled 'Study of ABO2102 in KRAS-Mutated Solid Tumors' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Suzhou Abogen Biosciences Co., Ltd.
Condition:
Advanced / Metastatic Solid Tumor
Intervention:
Drug: ABO2102 Injection
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: February 2026
Target Sample Size: 101
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07455617
Published by HT Digital Content ...